Free Trial
The Rate Lock Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 a Year
Claim MarketBeat All Access Sale Promotion

Wells Fargo & Company's Rating of Eli Lilly and Company on 10/30/2026

On October 30, 2026, Wells Fargo & Company updated its outlook on Eli Lilly and Company (NYSE:LLY) with the action "Boost Price Target", setting a price target of $1,500.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Wells Fargo & Company

DateCompanyAction
10/30/2026
Hershey Company (The) stock logo
HSY
Hershey
Lower Price Target
10/30/2026
Alphabet Inc. stock logo
GOOG
Alphabet
Reiterated Rating
10/30/2026
Intercontinental Exchange Inc. stock logo
ICE
Intercontinental Exchange
Boost Price Target
10/30/2026
Tradeweb Markets Inc. stock logo
TW
Tradeweb Markets
Boost Price Target
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Lower Price Target
10/30/2026
Incyte Corporation stock logo
INCY
Incyte
Lower Price Target
More Ratings From Wells Fargo & Company